Wilkes Public Health Dental Clinic Dentist Medicare: Not Enrolled in Medicare Practice Location: 1915 West Park Dr, Suite 104, N Wilkesboro, NC 28659 Phone: 336-903-7302 Fax: 336-903-0464 |
News Archive
A study led by University of Kentucky Markey Cancer Center researchers showed that patients who already used opioids, sedatives or antidepressants prior to colorectal surgery experience significantly more complications post-surgery.
Type 2 diabetes patients who are treated with dipeptidyl peptidase-4 inhibitors have a significantly reduced risk for cardiovascular events, particularly myocardial infarction, compared with their peers who take placebo or other drugs, results of a meta-analysis show.
Nebraska Governor Dave Heineman vetoed a proposal to restore Medicaid-funded prenatal care for illegal immigrants on Friday, but the initiative could still survive if the state legislature rejects his move next week. Nebraska state senators voted 31-15 on Wednesday to restore the program, which was eliminated two years ago after providing prenatal care for decades.
Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.
DaVita HealthCare Partners Inc. (NYSE: DVA) today announced results for the quarter ended September 30, 2013. Adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2013 was $211.0 million and $605.3 million, or $0.98 and $2.82 per share, respectively, excluding a loss contingency reserve. In addition, adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2013 excluded a contingent earn-out obligation adjustment. Income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2013 including these items was $136.6 million and $407.9 million, or $0.64 per share and $1.90 per share, respectively.
› Verified 3 days ago